share_log

信達生物:委任獨立非執行董事及變更戰略委員會組成

INNOVENT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE

香港交易所 ·  Feb 9 06:01
Summary by Moomoo AI
信達生物製藥有限公司宣布,自2024年2月9日起,陸舜博士將出任獨立非執行董事及戰略委員會成員。陸博士在醫療及製藥行業擁有超過30年經驗,曾在上海市胸科醫院擔任多個高級職位,並獲得多項學術及社會貢獻獎項。他的專業背景和豐富經驗被期待將為信達生物的發展帶來正面影響。根據公司組織章程大綱及細則,陸博士將在股東週年大會上輪值告退及重選連任,並未有收取任何薪酬。董事會對陸博士的加入表示熱烈歡迎。
信達生物製藥有限公司宣布,自2024年2月9日起,陸舜博士將出任獨立非執行董事及戰略委員會成員。陸博士在醫療及製藥行業擁有超過30年經驗,曾在上海市胸科醫院擔任多個高級職位,並獲得多項學術及社會貢獻獎項。他的專業背景和豐富經驗被期待將為信達生物的發展帶來正面影響。根據公司組織章程大綱及細則,陸博士將在股東週年大會上輪值告退及重選連任,並未有收取任何薪酬。董事會對陸博士的加入表示熱烈歡迎。
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT DR. LU SHUN WILL SERVE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE STRATEGIC COMMITTEE FROM FEBRUARY 9, 2024. Dr. Lu has more than 30 years of experience in the medical and pharmaceutical industry. He has held several senior positions at Shanghai Thoracic Hospital and has received numerous academic and social contributions awards. His professional background and wealth of experience are expected to have a positive impact on the development of Sinda organisms. In accordance with the Company's Articles of Association and Conditions, Dr. Lu will be retired and re-elected for a second term at the Annual General Meeting without any remuneration. The Board of Directors warmly welcomes Dr. Lu's accession.
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT DR. LU SHUN WILL SERVE AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE STRATEGIC COMMITTEE FROM FEBRUARY 9, 2024. Dr. Lu has more than 30 years of experience in the medical and pharmaceutical industry. He has held several senior positions at Shanghai Thoracic Hospital and has received numerous academic and social contributions awards. His professional background and wealth of experience are expected to have a positive impact on the development of Sinda organisms. In accordance with the Company's Articles of Association and Conditions, Dr. Lu will be retired and re-elected for a second term at the Annual General Meeting without any remuneration. The Board of Directors warmly welcomes Dr. Lu's accession.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more